In:
Annals of the New York Academy of Sciences, Wiley, Vol. 865, No. 1 ( 1998-12), p. 132-140
Abstract:
A bstract : Miniglucagon, or glucagon‐[19–29], is partially processed from glucagon in its target tissues where it modulates the glucagon action. In the islets of Langerhans, the glucagon‐producing A cells contain miniglucagon at a significant level (2–5% of the glucagon content). We studied a possible control of insulin release by miniglucagon using as a model the MIN6 cell line. Miniglucagon, in the 10 −14 to 10 −9 M range, inhibited insulin release induced by glucose, glucagon, tGLP‐1, or glibenclamide by 85–100% with an IC 50 close to 1 pM. While no change in the cyclic AMP content was noted, Ca 2+ influx was reduced in parallel with the inhibition of insulin release. Use of pharmacological modulators of L‐type voltage‐sensitive Ca 2+ channels and bacterial toxins indicates that miniglucagon blocks insulin release by closing this type of channel via a pertussis toxin‐sensitive G protein. Miniglucagon is a novel, possibly physiologically relevant, local regulator of islet function.
Type of Medium:
Online Resource
ISSN:
0077-8923
,
1749-6632
DOI:
10.1111/nyas.1998.865.issue-1
DOI:
10.1111/j.1749-6632.1998.tb11171.x
Language:
English
Publisher:
Wiley
Publication Date:
1998
detail.hit.zdb_id:
2834079-6
detail.hit.zdb_id:
211003-9
detail.hit.zdb_id:
2071584-5
SSG:
11
Permalink